Genomas, Inc.

Press Releases

Date	Release
3/4/2013	Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
10/13/2011	Genomas Awarded US Patent for PhyzioType System to Predict Cardio-Metabolic Side Effects of Psychiatric Drugs
8/12/2011	Genomas Companion Studies Offer Promise for Personalized Management of Psychotropic Therapy
6/1/2011	Genomas Awarded $1.3 Million NIH SBIR Grant to Bring to Market DNA-Guided Statin Therapy
9/13/2010	Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
9/22/2009	Genomas Receives Award as The Most Promising Life Sciences Company of the Year, Connecticut Technology Council’s 2009 Innovation Pipeline Awards
9/15/2009	Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness
7/14/2009	Genomas Celebrates 5th Anniversary at Hartford Hospital
6/15/2009	Genomas Presents Drug-specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis
5/21/2009	Genomas and Institute of Living Among Organizers of Pharmacogenetics Symposium at 2009 Annual Meeting of the American Psychiatric Association
2/12/2009	American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruaño to College of Fellows
1/21/2009	Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
12/9/2008	Genomas Clinical Study Finds Increased Prevalence of Drug Metabolism Deficiencies in Patients with Serious Psychotropic Side Effects
9/24/2008	Connecticut State Medical Society and Genomas Co-sponsor Forum on DNA-guided Medicine and Path to Personalized Health Care
7/28/2008	Genomas Presents New Findings On Statin Safety And Patient Adherence
3/19/2008	Genomas Awarded $1.2 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Statin Therapy
9/20/2007	Neuromuscular Side Effects of Statins Linked to Pain Perceptions by Physiogenomics Technology at Genomas
6/24/2007	Genomas Awarded $1.4 Million NIH SBIR Grant to Develop DNA-Guided System for Management of Psychotropic Therapy
1/4/2007	Genomas Announces Physiogenomic Study That Reveals Potential Cause of Metabolic Side Effects in Patients Treated with Psychotropic Drugs
10/18/2006	The Hospital of Central Connecticut and Genomas Establish Strategic Partnership in DNA-Guided Management of Diabetes
12/1/2005	Statin Safety Linked to Vascular Genes by Novel PhysioGenomics™ Technology at Genomas
10/26/2005	Personalized Medicine Forum at MEDi 2005 to be Chaired by Genomas President, Recipient of the Beacon Medical Technology Award
10/26/2005	First DNA Diagnostic System for Personalized Drug Safety Launched by Genomas and Clinical Laboratory Partners
10/4/2005	Genomas Awarded SBIR Grants Totaling $500,000 from the National Institutes of Health in Partnership with the Institute of Living
6/10/2005	Genomas Forum Explores "Diet and DNA" at the 10th Annual International Festival of Arts & Ideas in New Haven
6/3/2005	Genomas Co-Sponsors Major Impressionist Exhibition at Wadsworth Atheneum Museum of Art
5/24/2005	Genomas Launches Laboratory of Personalized Health and Announces Appointment of Its President as Fellow of the National Academy of Clinical Biochemistry
3/2/2005	Genomas Announces Appointments of Board Director and Business Advisors
1/26/2005	Genomas Appoints Chief Technology Officer and Chief Biostatistics Consultant
11/15/2004	Genomas and the University of Connecticut Establish Collaboration on Personalized Diet for Treatment of Obesity and Metabolic Syndrome
8/10/2004	Genomas Names Robert W. Scherrer Chief Financial Officer
7/20/2004	Genomas And Illumina Form Strategic Alliance On Physiogenomics Of Metabolic Syndrome
6/7/2004	New Era of Healthcare Opening to Public Through Hartford Hospital and Genomas
5/12/2004	Dr. Gualberto Ruaño Is Elected To Prestigious Connecticut Academy Of Science And Engineering
10/20/2003	Dr. Gualberto Ruaño Named to George Washington University Faculty Genomas Founder to Be Involved in New Genomics and Regulatory Aspects of Research Endeavors at the Nation's Capital.
9/15/2003	Biotech Innovator Founds New Company to Enhance Health Gualberto Ruaño's Genomas will Apply Genomics to Disease Prevention